CD4 and neoplasm: Moreover, treatment with crizotinib or αPD-1 alone promoted greater numbers of tumor-infiltrating CD8+ T cells (Fig. 5g, Supplementary Fig. 5g), IFN-γ+granzyme B+CD8+ T cells (Fig. 5h), and T effector (Teff) subsets (Th1) of CD4+ T cells (Fig. 5i, Supplementary Fig. 5h) in tumors than did treatment with the vehicle but substantially fewer than did the combination treatment (Fig. 5g–i).